DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Given Average Rating of “Hold” by Analysts

Shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) have received an average recommendation of “Hold” from the fifteen brokerages that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $14.4167.

Several research analysts recently weighed in on XRAY shares. UBS Group reduced their price target on DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Zacks Research raised shares of DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a research note on Monday, March 2nd. Mizuho lifted their target price on shares of DENTSPLY SIRONA from $14.00 to $16.00 and gave the company a “neutral” rating in a report on Monday, March 2nd. Barrington Research increased their price target on shares of DENTSPLY SIRONA from $14.00 to $17.00 and gave the stock an “outperform” rating in a report on Monday, March 2nd. Finally, Wells Fargo & Company raised their price target on shares of DENTSPLY SIRONA from $12.00 to $13.00 and gave the company an “equal weight” rating in a research report on Friday, February 27th.

More DENTSPLY SIRONA News

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: FDA clearance for a dental‑dedicated MRI (ddMRI) with Siemens Healthineers: this first‑of‑its‑kind imaging system expands XRAY’s advanced‑imaging addressable market and could drive higher‑margin equipment sales and recurring service revenue over time. First-ever Dental Dedicated MRI Validated…
• Positive Sentiment: Insider buying from directors (James Forbes and Gregory Lucier): recent purchases (~$12.45–$12.48/share) signal management/board confidence in the stock at current levels and can support sentiment if the buys continue. DENTSPLY SIRONA (NASDAQ:XRAY) Director James Forbes Buys 5,000 Shares
• Neutral Sentiment: Analysts are reworking valuation and risk assumptions: coverage shifts and updated models (discussed in a Yahoo Finance piece) are causing targets and ratings to be revisited — this fuels near‑term volatility but could clarify consensus levels over weeks. How The Dentsply Sirona (XRAY) Story Is Shifting…
• Neutral Sentiment: Presentation transcript from the Leerink Global Healthcare Conference: useful for incremental detail on strategy, margin actions and product cadence — may influence analyst revisions but no single headline takeaway. DENTSPLY SIRONA Presents at Leerink…
• Neutral Sentiment: Short‑interest reports show data anomalies (reported as 0 shares / 0 days to cover) — current disclosures appear unreliable, so there is no clear short‑squeeze or elevated short‑pressure signal from these entries. (Data point: average volume references included in filings.)
• Negative Sentiment: Recent quarterly results/earnings mix: revenue beat but an EPS miss and a negative net margin keep focus on profitability and leverage (market cap and leverage metrics remain notable). Analysts’ target adjustments are mixed (some cuts, some raises), leaving consensus at a “Hold” with average target ~$14.4 — downside remains if execution or margin recovery slows. DENTSPLY SIRONA (XRAY) MarketBeat summary

DENTSPLY SIRONA Stock Down 0.9%

NASDAQ:XRAY opened at $12.68 on Wednesday. The company has a debt-to-equity ratio of 1.50, a current ratio of 1.51 and a quick ratio of 1.03. The company’s fifty day moving average price is $12.69 and its 200-day moving average price is $12.43. DENTSPLY SIRONA has a 1-year low of $9.85 and a 1-year high of $17.18. The firm has a market capitalization of $2.53 billion, a P/E ratio of -4.23, a PEG ratio of 1.50 and a beta of 0.97.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). The business had revenue of $961.00 million for the quarter, compared to analyst estimates of $926.40 million. DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.26 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, equities research analysts anticipate that DENTSPLY SIRONA will post 1.84 EPS for the current year.

Insider Activity

In other DENTSPLY SIRONA news, Director James D. Forbes purchased 5,000 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The stock was purchased at an average price of $12.48 per share, for a total transaction of $62,400.00. Following the purchase, the director directly owned 10,000 shares in the company, valued at approximately $124,800. This trade represents a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gregory T. Lucier purchased 27,555 shares of the stock in a transaction on Monday, March 2nd. The shares were acquired at an average price of $14.24 per share, for a total transaction of $392,383.20. Following the transaction, the director directly owned 27,555 shares of the company’s stock, valued at $392,383.20. This represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders purchased 70,000 shares of company stock valued at $956,437. 0.52% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Mitsubishi UFJ Trust & Banking Corp increased its holdings in shares of DENTSPLY SIRONA by 1,836.7% in the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 105,938 shares of the medical instruments supplier’s stock valued at $1,344,000 after purchasing an additional 100,468 shares during the last quarter. Bank of Montreal Can boosted its stake in DENTSPLY SIRONA by 8.2% during the second quarter. Bank of Montreal Can now owns 352,524 shares of the medical instruments supplier’s stock worth $5,598,000 after buying an additional 26,610 shares during the last quarter. Commonwealth Equity Services LLC boosted its stake in DENTSPLY SIRONA by 38.4% during the third quarter. Commonwealth Equity Services LLC now owns 804,934 shares of the medical instruments supplier’s stock worth $10,215,000 after buying an additional 223,339 shares during the last quarter. CWM LLC grew its holdings in DENTSPLY SIRONA by 84.3% in the 3rd quarter. CWM LLC now owns 420,470 shares of the medical instruments supplier’s stock valued at $5,336,000 after buying an additional 192,373 shares in the last quarter. Finally, Advisors Asset Management Inc. increased its stake in shares of DENTSPLY SIRONA by 42.8% in the 3rd quarter. Advisors Asset Management Inc. now owns 348,989 shares of the medical instruments supplier’s stock worth $4,429,000 after acquiring an additional 104,588 shares during the last quarter. Hedge funds and other institutional investors own 95.70% of the company’s stock.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.